Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics (NASDAQ: ANIK) announced that on April 1, 2026 it granted restricted stock units covering an aggregate of 3,138 shares to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Summary
Anika Therapeutics (NASDAQ: ANIK) announced that on April 1, 2026 it granted restricted stock units covering an aggregate of 3,138 shares to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4).
The RSUs were approved under the Anika Therapeutics 2021 Inducement Plan by the compensation committee, do not require stockholder approval, and vest in three equal annual installments subject to continued service and the equity award agreement terms.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ANIK
In the Apr 6 session, ANIK declined 0.34%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- RSU grant size
- 3,138 shares
- Aggregate restricted stock units for one new non-executive employee
- Vesting schedule
- 3 installments
- RSUs vest in three equal annual tranches from April 1, 2026 grant
Historical Context
-
Reported Q4 and FY 2025 results with margin expansion and 2026 guidance.
-
Announced CEO presentation and investor meetings at a musculoskeletal conference.
-
Scheduled release date and call details for Q4 and year-end 2025 results.
-
Lumicell added Anika’s Executive Chair to its board, highlighting her experience.
-
Announced CEO change, new Executive Chair, lead director, and reaffirmed 2025 guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
rsus financial
nasdaq listing rule 5635(c)(4) regulatory
equity award agreement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
The RSUs will vest in three equal installments on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
The RSUs are subject to the terms and conditions of the equity award agreement approved by Anika. The RSUs were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.